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Fanconi anemia (FA) is a recessive DNA instability disorder associated with developmental abnormalities, bone marrow failure,
and a predisposition to cancer. Based on their sensitivity to DNA cross-linking agents, FA cells have been assigned to 15
complementation groups, and the associated genes have been identiﬁed. Founder mutations have been found in diﬀerent FA genes
in several populations. The majority of Dutch FA patients belongs to complementation group FA-C. Here, we report 15 patients
of Dutch ancestry and a large Canadian Manitoba Mennonite kindred carrying the FANCC c.67delG mutation. Genealogical
investigation into the ancestors of the Dutch patients shows that these ancestors lived in four distinct areas in The Netherlands.
We also show that the Dutch and Manitoba Mennonite FANCC c.67delG patients share the same haplotype surrounding this
mutation, indicating a common founder.
1.Introduction
Fanconi anemia is an inherited chromosomal instability
disorder associated with developmental abnormalities, bone
marrow failure, and a predisposition to cancer. A character-
istic feature of FA cells is their hypersensitivity to DNA cross-
linking agents such as diepoxybutane (DEB) and mitomycin
C (MMC). This feature has been used to assign FA cells to
diﬀerent complementation groups. Currently, 15 diﬀerent
complementation groups and their associated genes have
been identiﬁed. Of these, 14 have an autosomal recessive,
and one has an X-linked, mode of inheritance [1–3]. The
majority of FA patients belong to complementation group
FA-A (65%) followed in frequency by FA-C (10%) and FA-G
(10%) [4].
The incidence of FA is approximately 1 in 130,000 live
births, with a carrier frequency of approximately 1 in 181
[5]. In some ethnic groups, however, the incidence is much
higher due to genetic isolation and a founder eﬀect. For
example, founder mutations in the FANCA gene have been
found in several populations including the South African
Afrikaners, Spanish Gypsies, and Moroccan Israeli Jews [6–
8]. Furthermore, sub-Saharan Blacks and Japanese carry
founder mutations in the FANCG gene [9, 10]. In addition,
FANCC c.456 + 4A > T (also known as IVS4 + 4A > T) is
a previously identiﬁed founder mutation in the FANCC gene2 Anemia
intheAshkenaziJewishpopulation [11,12].Remarkably,the
FANCC c.456 + 4A > T mutation has a severe phenotype
in Ashkenazi Jews, but a milder phenotype in Japanese FA
patients, suggesting the presence of unidentiﬁed modifying
factors [13]. The majority of Dutch FA patients belong to
complementation group FA-C, with c.67delG (also known as
322delG) being the predominant mutation ([14], personal
communication H. Joenje). In this paper, we report 15
patients of Dutch ancestry and a large Canadian Mani-
toba Mennonite kindred harbouring the FANCC c.67delG
mutation. The presence of the FANCC c.67delG mutation
in this kindred together with the fact that the Mennonites
arose in The Netherlands around 1550–1600 AD suggested
a common founder for the Dutch and Mennonite c.67delG
mutation. We demonstrate that the Dutch and Manitoba
Mennonite FANCC c.67delG patients do, in fact, share the
same haplotype surrounding this mutation, indicating a
common genetic origin.
2.MaterialsandMethods
2.1.DutchPatients. All15patientswiththeFANCC c.67delG
mutation lived in The Netherlands except VU449, VU654,
and VU911 who lived in the United Kingdom, Northern
France, and Canada, respectively and had Dutch grand
and great grandparents. The FA diagnosis was based on
clinical symptoms suggestive of FA, in combination with a
positive result from a chromosomal breakage test using a
standard DNA cross-linking agent. Classiﬁcation as an FA-C
patientwasbasedoncomplementationstudiesorsequencing
analysis.
Genomic DNA was isolated from ﬁbroblasts, blood, or
lymphoblastoid cell lines from previously diagnosed FANCC
c.67delG patients using the Qiagen Blood mini kit (Qiagen,
Venlo, The Netherlands).
2.2. Canadian Manitoba Mennonite Family. The proband of
this family was diagnosed with FA at the age of ﬁve years,
when she presented with bone marrow failure. At birth,
there was documented intrauterine growth retardation, joint
contractures, and a ventricular septal defect. At the time
of presentation, the proband was also noted to be of small
stature and to have a triangular facies and multiple caf´ e-
au-lait macules. She died at the age of six years from com-
plications following allogeneic bone marrow transplantation
from her HLA-identical sibling. A younger sibling (VU1454)
was subsequently diagnosed with FA and was found to
be homozygous for the FANCC c.67delG mutation. She
had normal growth parameters at birth and no noted FA-
associated anomalies except for the development of caf´ e-au-
lait macules.
A ﬁeld trip was conducted to the rural community in
which this family lived, and family members were given an
FA information session. Forty-ﬁve members of the extended
family consented to participate in this study. Clinical his-
tories were obtained, and cheek swabs were collected for
genotyping. Minors who provided assent or whose parents
consented on their behalf were also included in the study.
2.3. Genotype Analysis. Patients and family members were
genotypedusingﬂuorescentlylabelledmicrosatellitemarkers
and single-nucleotide polymorphisms (SNPs) in an 8Mb
region surrounding the FANCC gene. Markers used were the
CA repeat markers D9S1842, D9S1781, D9S197, D9S1689,
D9S1816, D9S1809, D9S1851, D9S180, and D9S176. Ampli-
ﬁcation of the CA repeat markers was performed with the
GeneAmp PCR system 9700 (Applied Biosystems, Foster
City, CA, USA). Samples were analyzed on ABI 3730 or
ABI 310 DNA Analyzer (Applied Biosystems, Foster City,
CA, USA). SNPs used were rs1331216, rs2277182, and
rs1016013. Ampliﬁcation of the SNPs was performed with
the GeneAmp PCR system 9700, and the PCR products
were puriﬁed using a SAP/EXO treatment (Amersham
Biosciences, Uppsala, Sweden) according to manufacturer’s
instructions. Sequencing was performed with the Big Dye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA, USA). Samples were analyzed on an ABI
3730 DNA Analyzer (Applied Biosystems, Foster City, CA,
USA).
GenotypingoftheCanadianpatientandfamilymembers
for the FANCC c.67delG mutation was performed using
standard methods (GeneDx, Inc., Gaithersburg, MD, USA).
In brief, an allele-speciﬁc assay was designed to detect the
presence of the single base deletion, and all samples showing
the heterozygous presence of the deleted G nucleotide were
sequenced bidirectionally to conﬁrm the ﬁndings.
3. Results
Eleven of the 15 FA-C patients of Dutch ancestry analyzed
in this study were homozygous for the c.67delG mutation,
and 4 were compound heterozygous, each with a diﬀerent
second mutation. Using polymorphic microsatellite markers
and SNPs, the smallest common haplotype in the 26
alleles harbouring the c.67delG mutation was determined
to be 0.8Mb, covering the region from rs1016013 until
D9S1816 (Table 1(a)). A larger common haplotype of 2Mb
(D9S197-D9S1816) was found in 23 alleles. The 3 alleles
responsible for the decrease of 1.2Mb in the common hap-
lotype belonged to 3 sibs (VU1134, VU1135, and VU1136)
homozygous for the c.67delG mutation. The presence of two
partially diﬀering haplotypes in these homozygous c.67delG
patients was conﬁrmed in the parents (results not shown).
The identical haplotype surrounding the c.67delG mutation
indicates that all 15 FA patients have coinherited this stretch
of DNA from a common ancestor. The expected size of
a co-inherited stretch of DNA can be estimated by the
equation 200/(number of meioses), which is based on the
assumption that recombinants occurring in meioses from
the ﬁrst common founder on either side of the mutation are
uniformly distributed over the interval of 0 to 100Mb [15].
This indicates that the descent tree of the 15 FA patients, up
to the common founder, given a shared common stretch of
DNA of approximately 0.8Mb, counts about 250 meioses.
This corresponds to about 10–20 generations and a common
founder living in the 16–18th centuries.
Genealogical investigations into the ancestors of these
patients only retrieved 6 or 7 generations from the archives,Anemia 3
Table 1: The haplotype associated with the FANCC c.67delG mutation determined in 15 patients of Dutch ancestry (Table 1(a)) and in the
aﬀected sib of the proband, the parents, and healthy sibs of the Mennonite kindred (Table 1(b)). In Table 1(a) simpliﬁed, deducted allele
lengths are shown and in Table 1(b) the observed allele lengths are shown. For comparison, patient VU1135 is included in both tables. The
dark grey boxes shows the smallest common haplotype of 0.8Mb. The light and dark grey box, together show the larger common haplotype
of 2Mb. The boxed areas indicate homozygosity for the relevant markers. At the top, the distances in Mb of the markers to the c.67delG
mutation are indicated. Patients VU001 and VU002 are siblings as well as patients VU1134, VU1135, and VU1136.
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VU002 4 1 1 4 C G C delG 1 4 3 1 2
5114C G C d e l G 12216
VU158 6 1 1 4 C G C delG 1 4 3 1 2
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VU166 2 3 1 4 C G C delG 1 1 1 2
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7114C G C d e l G 13337
3644TGT 33222
VU811 1 1 1 4 C G C delG 1 4 3 1 2
7114C G C d e l G 14434
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3523TAC d e l G 14314
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5453T T 15221
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VU1135 147 160 201 92 C G C delG 151 140 220 137
151 166 212 90 T A C delG 151 140 220 137
Affected sib 150 146 201 92 C G C delG 151 140 220 145
(VU1454) 150 146 201 92 C G C delG 151 140 220 133
Mother 150 146 201 92 C G C delG 151 140 220 145
148 146 201 92 C G C — 157 136 228 137
Father 150 201 C G C delG 151 220 133
148 211 C G C — 159 220 131
sib1 150 201 92 C G C delG 151 140 220 145
148 211 92 C G C — 159 126 220 131
sib2 150 146 201 92 C G C delG 151 140 220 145
148 146 211 92 C G C — 159 126 220 133
and therefore it was not possible to reveal the common
ancestor. However, for patient VU166 and patient VU1131,
a common ancestor couple was found living around 1800
AD, and consanguinity was shown for patients VU166,
VU1134, VU1135, and VU1136 (Figure 1). Our genealogical
investigations also showed that most of these 6th and
7th generation ancestors lived in 4 distinct areas in The
Netherlands (Figure 2), further supporting the possibility of
a single common ancestor.
Forty-ﬁve individuals in the Manitoba family were
genotyped for the FANCC c.67delG mutation. Eighteen
of the 45 (40%) participants were heterozygous for the
FANCC c.67delG mutation, and no new homozygotes were
identiﬁed. The medical histories collected from kindred
members did not reveal any early-onset cancer, but did
document several other disorders already known to be
overrepresented in the Manitoba Mennonite population,
including severe combined immunodeﬁciency (SCID) (C.R.
Greenberg, unpublished observation) and hypertrophic car-
diomyopathy (HCM) [16]. Consanguinity could not be
shown in ﬁve generations of ancestors. Haplotype analysis
was done on the aﬀected sib, two unaﬀected sibs, and
the parents of the proband; it revealed the same common
haplotype as found in the Dutch FANCC c.67delG patients
(Table 1(b)).
4. Discussion
This paper shows that c.67delG in FANCC is a founder
mutation that has probably originated in The Netherlands.
∗1793 ∗1800 ∗1831 ∗1831
VU166 VU1131
VU1134 VU1135 VU1136
Figure 1: Pedigrees showing consanguinity for patients VU166 and
VU1134/35/36. Common ancestors of patients VU166 and VU1131
were found living around 1800. ∗year of birth.
This Dutch mutation is also present in a large Mennonite
kindred with members living in the province of Manitoba,
Canada, and in the United States. The Mennonites are a
religious denomination named after one of its founders,
Menno Simons, who was born in 1496 in The Netherlands
in the province of Friesland, which is the area where the
ancestors of the Dutch c.67delG patient VU811 lived. They
ﬂed religious persecution over the centuries to the east andAnemia 5
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Figure 2: Domicile of the ancestors of patients. VU811 (area A), VU166, VU1131, and VU1134/35/36 (area B), VU239 (area C), and VU806
(area D). Ancestors of patients VU001 and VU002 lived in area B, C, and D. Ancestors of patient VU158 lived in areas C and D.
Russia, and from there to other parts of the world, and
many settled in western Canada during the 19th century
[17]. It is therefore likely that the Manitoba Mennonite FA-C
patientsinthisstudyweredescendedfromthesamecommon
ancestor as the Dutch patients in this study. This founder
must have lived more than 200 years ago, since genealogical
investigationcouldnotidentifythecommonancestoramong
the ancestors living after 1800 AD.
Even though the c.67delG mutation is generally thought
to be a mild mutation probably due to FAC polypeptide
isoforms retaining partial function leading to a mild disease
phenotype [18], clinical variability can be seen. The aﬀected
Mannitoba Mennonite siblings showed apparent divergent
phenotypes, but neither had skeletal abnormalities, a char-
acteristic of the mild disease phenotype associated with the
c.67delG mutation.
Based on the high degree of consanguinity, the presence
of the Dutch founder mutation, and the geographic origin
being The Netherlands, we suspect that the carrier frequency
for this c.67delG mutation in the North American Mennon-
ite population is higher than expected for a rare recessive
trait. An unselected and unbiased survey would be required
in order to determine the actual FANCC carrier frequency
in this Mennonite population. Several genetic disorders are
well known to be overrepresented in this population, but FA
has not previously been included in this list. Both HCM and
17 alpha-hydroxylase deﬁciency have previously been shown
to be caused by Dutch founder mutations [19–21]a m o n g
theMennonites.Sincepresentgenerationscontinuetomarry
according to traditional custom, we may see an increased
frequency of FA-C patients in future generations. Therefore,
Mennonite communities should be oﬀered comprehensive
genetic counselling and carrier testing for FA.
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